For years, psychedelics lived on the fringe, whispered about in documentaries, wellness circles, and a handful of academic labs.
That is not the world investors are looking at now.
The conversation has moved into the largest megaphones on earth, including Joe Rogan’s platform, where episodes with figures like Rick Doblin, plus public officials discussing psychedelic medicine, pulled the topic into everyday market talk.1
It has also moved into the most visible rooms where policy and capital collide.
In June 2025, Denver hosted Psychedelic Science 2025, a five day conference that Axios reported was expected to draw more than 7,000 attendees and more than 500 speakers, with lawmakers participating too.2
That is not a fringe meet up.
That is an industry organizing itself in public.
Then came the kind of headline that turns a “future maybe” into a “right now” signal.
In August 2025, Antonio Gracias, a billionaire investor closely tied to Elon Musk, helped seize control of Lykos Therapeutics, the most prominent MDMA therapy company in the US, backed by a $50 million recapitalization after the FDA rejection.3
Money moved in after a setback.
Investors notice that pattern.
Now add Washington.
In December 2025, the White House issued an executive order directing the Attorney General to expedite completion of the process of rescheduling weed to Schedule III, a reminder that rescheduling is a real mechanism inside the federal system, even when the paperwork takes time.4
Reuters described the order as restarting momentum around the Schedule I to Schedule III process, without claiming the order itself instantly rewrote the law.5
That blueprint is why investors are now tracking the next set of substances.
The DEA released its 2026 aggregate production quotas in early January 2026, with the agency noting the final order took effect January 5, 2026.6 Reporting on the final rule also highlighted a sharp step up in the psilocybin quota, from 36,000 grams in 2025 to 80,000 grams for 2026, a practical sign that authorized research capacity is being prepared to scale.7
Then there is the part most investors underestimate, the infrastructure is already being built in plain sight.
A 2025 Psychology Today analysis said at least a thousand clinics in the US offer ketamine assisted therapy off label, showing how fast a clinic network can spread once demand shows up.8
Here is the part most investors still miss.
In every new medicine wave, the first real bottleneck is not excitement, it is legal supply.
Someone has to be licensed, inspected, and capable of producing consistent dosage forms, then shipping them through regulated channels.
And that “picks and shovels” layer is exactly where one tiny public company is trying to position itself, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF).
Top 8 Reasons
Investors Are Paying Attention Right Now
Psychedelics have moved from niche talk into mainstream culture. The shift is visible in the rooms where money and policy intersect. Denver’s Psychedelic Science 2025 conference is one example, with Axios reporting more than 7,000 attendees expected, more than 500 speakers, and participation from lawmakers.9 Capital tends to follow moments like this. Quietly at first. Then all at once.
For investors, the bigger question is not who has the loudest pipeline. It is who can legally supply the category as regulated channels open. That is the lane Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is targeting.
1
The conversation went mainstream. Capital tends to follow attention.
Large scale events and mainstream platforms have normalized the topic. The result is a broader investor audience watching the space again. Momentum like that often brings new funding, new partnerships, and faster progress.
2
The shakeout is real. Serious capital is still showing up.
After the FDA rejection, The Guardian reported that Antonio Gracias, a billionaire investor closely tied to Elon Musk, helped recapitalize and take control of Lykos Therapeutics with a $50 million recapitalization.10 That kind of move is not built on hype. It is built on the belief that the category still has a commercial future.
3
Australia is live. Prescribing is happening under strict controls.
Australia’s TGA has stated that authorized psychiatrists can prescribe MDMA and psilocybin for specific conditions under strict controls beginning July 1, 2023.11 A live prescription pathway changes the tone of the entire sector. It creates real procurement. Real ordering. Real demand signals.
4
Reimbursement is the unlock. It turns interest into repeat demand.
Optimi’s MDMA export announcement tied its shipment to PTSD therapy under the Authorised Prescriber Scheme and referenced the Australian Department of Veterans’ Affairs funding MDMA assisted therapy for veterans with PTSD.12 Funding is what makes a channel stick. It is what keeps orders coming back. This is also where Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) fits, on the supply side, where repeat orders can translate into measurable throughput.
5
The supply chain is the choke point. Licenses and GMP decide who can scale.
Controlled substances are a compliance business. Health Canada’s inspection database shows Optimi Labs Inc. listed with compliant inspection outcomes.13 When demand rises, the companies with quality systems, documentation, storage, and shipping discipline are the ones that can keep up.
6
Direct to clinic supply is easier to follow than long trial timelines.
Most public psychedelic names trade on trial milestones. Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has leaned into regulated supply and commercial execution, including the way it describes its business in its SEC Form F 1 filing.14 Optimi also announced a commercial psilocybin capsule launch in Australia for treatment resistant depression under the Authorised Prescriber pathway.15
7
Real world data builds credibility over time.
Australia’s TGA frames MDMA and psilocybin as unapproved therapeutic goods accessed under strict pathways.16 In a category like this, clean operations and traceable product matter. Over time, real world outcomes and consistent supply can add weight to the story.
8
The stock is still priced like an early chapter. The theme is getting louder.
Optimi remains a microcap trading on the CSE and OTCQX, while the sector is drawing national media attention and institutional scale events.17,18 When attention expands first, the supply side names can stay overlooked longer than expected.
Next comes the practical part. What Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) actually does. How it manufactures. How it ships. How it plugs into regulated clinic channels that are already operating today.
The Quiet Power Behind Psychedelic Medicine. Licensed Manufacturing. Real Product. Real Supply.
Most investors hear “psychedelics” and picture scientists, lab coats, and long clinical timelines.
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is positioned in a different part of the chain.
It focuses on making the actual regulated product, in a form clinics can order, pharmacies can handle, and regulators can approve for import and export paperwork.
To understand the business, it helps to picture how a prescription capsule gets made.
First, there is the “starting material.” For psilocybin, Optimi describes a vertically integrated process that can include cultivation, extraction, formulation, and encapsulation, all handled in house at its GMP licensed facility in British Columbia.20
Then there is the “finished dosage form.” That is a fancy phrase for the final product a patient receives, for example a capsule with a specific amount inside it, like 5 mg psilocybin capsules, or MDMA capsules in 40 mg and 60 mg strengths.21,22
This is where the “boring” work becomes the moat.
A regulated capsule is not just powder in a shell.
It has to be consistent. Every capsule has to match the label. It has to be tested. It has to be tracked. It has to meet manufacturing standards, and it has to clear multiple layers of paperwork before it can cross a border.
That is why licenses and inspections are a big part of what Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has been building.
Health Canada issues licenses for drug manufacturing and regulated controlled substances. Optimi has described holding a Drug Establishment Licence, which is the type of licence that supports manufacturing and sale of its MDMA and psilocybin capsules, and it links that licence to GMP compliance.23
Optimi also describes holding a Dealer’s Licence under Canada’s controlled substances rules, which it says authorizes possession, production, assembling, sale, and delivery of certain substances within the licence terms. In its SEC filing, Optimi includes specific possession limits for psilocybin, psilocin, and MDMA under that licence.24
A simple way to think about it is this.
The Dealer’s Licence is about what the company is allowed to handle.
The Drug Establishment Licence is about how the company is allowed to manufacture and sell a drug product.
And inspections are about whether it is following the rules in practice.
Health Canada’s inspection database includes an inspection detail page for Optimi Labs Inc. at the Princeton, British Columbia address.25
That is not the fun part of the story.
But it is the part that tends to decide who can ship, who can scale, and who gets stuck watching others move first.
Once the product is made, the next step is testing.
For example, Optimi’s (CSE:OPTI) (OTCQX:OPTHF) Australia psilocybin capsule launch says the shipment followed independent Certificate of Analysis testing to confirm compliance with Australia’s specifications.26
Think of it like a report card for the batch.
It checks what is inside. It checks purity. It checks consistency. It checks that the product matches what regulators expect.
Only then does the export process start.
That means multiple approvals, and multiple agencies.
In the same psilocybin capsule release, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) says the export was completed with clearance from Health Canada, Australia’s TGA, and Australia’s BICON Biosecurity Authority.27
This is the part most investors underestimate.
A company can talk about a future market all day.
But if it cannot clear the paperwork, the product does not move.
Optimi has been trying to show real movement.
On May 8, 2025, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced its largest international export to date of MDMA capsules to Australia, and saying import approval was granted by Australia’s TGA with matching export permits from Health Canada, shipped under its Drug Establishment Licence.28
On September 3, 2025, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced the commercial launch of its natural psilocybin capsules in Australia, describing an initial shipment of 1,000 capsules, each containing 5 mg of standardized naturally derived psilocybin, manufactured in house at its GMP licensed facility.29
Those two announcements also show another key part of what Optimi does.
It is not only making a substance, it is making a product.
A product is what clinics can actually use inside a regulated system.
It has a set dose. It has a label. It has test paperwork. It has a chain of custody. It fits into ordering and dispensing systems.
Optimi also highlights working with Mind Medicine Australia as a commercial partner, with Optimi saying the partner will oversee distribution and patient coordination through Australia’s network of clinics and hospitals.30 The MDMA export release describes the shipment as conducted in partnership with Mind Medicine Australia.31
Optimi also announced it was selected to supply GMP 40mg and 60mg MDMA capsules for MAPS Israel’s Ministry of Health–approved PTSD clinical trial (sponsored by Sheba Medical Center), and said it has completed the first export of those capsules to Israel for the program.32
In plain English, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is trying to be the company that can reliably fill orders.
Not just talk about demand.
This is where the urgency sneaks in.
Licenses are slow. Inspections are detailed. Export permits are paperwork heavy. Batch testing takes time. Stable supply takes repetition.
A lot of companies want to participate in this category.
Very few can do the dull parts well enough to ship product into a regulated prescription market, then do it again and again.
That is the bet behind Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF).
The company is trying to position itself where the first legal channels are already open, and where supply has to be controlled and consistent.
Australia Is The Proof. The Pipeline Is Real, The Orders Come Next.
The biggest investment stories rarely start with a stock chart.
They start with pressure.
And there is no shortage of pressure in mental health.
IHME’s mental health work highlights the scale of the burden globally, with anxiety and depressive disorders among the leading causes of health loss.33
That burden already supports a massive existing treatment market, Grand View Research estimates the global anxiety disorders and depression treatment market at about $15.42 billion in 2024, projecting about $19.28 billion by 2030.34
Now layer in the part most investors are only starting to notice.
Psychedelics are not just a discussion anymore.
They are turning into a regulated supply chain.
Australia is the cleanest example, because it is already live.
Australia’s regulator, the TGA, has stated that authorized psychiatrists can prescribe Molly and psilocybin for specific conditions under strict controls, starting July 1, 2023.35
That one policy shift creates something investors can measure. A real channel. Real prescribing. Real clinics. And the first thing that follows is not hype.
It is ordering.
Repeat ordering is where the story changes.
A clinic does not buy product once and disappear.
If the program continues, it needs more product for the next patient. The next cohort. The next month.
That is how a “new category” turns into a repeatable business rhythm, purchase orders, shipments, reorders, and a growing network of programs.
This is why Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) sits in a very specific lane.
Optimi is not trying to win by promising a single miracle headline.
It is trying to win by being the supplier that can legally fill orders inside a regulated market, as that market expands.
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has described shipping GMP MDMA capsules into Australia and launching natural psilocybin capsules into the Australian prescription channel.36,37
While Australia provides the real world wedge, the broader system is also sending quiet signals that more throughput is coming.
The DEA’s 2026 final rule increased legal production quotas for certain psychedelics used for research and authorized production, and Weed Moment summarized that psilocybin’s quota rose from 36,000 grams in 2025 to 80,000 grams for 2026.38
At the same time, the market has learned to respect reality.
The FDA declined to approve Lykos’s MDMA based PTSD treatment in August 2024, Reuters reported the agency asked for an additional late stage trial.39
And yet big money keeps leaning in.
Reuters reported AbbVie agreed to acquire Gilgamesh’s psychedelic inspired depression program for up to $1.2 billion.40
Even the US policy conversation is starting to surface more openly, PBS reported comments from Robert F. Kennedy Jr. suggesting psychedelic therapy for depression and trauma has support within the Trump administration.41
No one gets to promise the timeline.
But investors do get to choose positioning.
Australia is already showing what a regulated market looks like.
Repeat orders are the signal that the channel is working.
And a microcap supplier like Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is trying to prove it can sit in the middle of that channel before the crowd wakes up.
The Manufacturing Moat. The Toll Booth In A Regulated Market.
In psychedelics, demand is not the hard part.
Legal supply is.
These are controlled substances moving through medical channels, so the winners are the ones who can manufacture the same product, the same way, every time, with paperwork that holds up under inspection.
That is what GMP is built for. Health Canada describes GMP as quality assurance that helps ensure drugs are consistently produced and controlled to the right standards.42
Now add the real bottleneck.
Capacity without compliance does not count.
A company can claim it can make product, but regulators decide whether it can legally ship it, and clinics decide whether they trust it.
That is why the scarce advantage becomes “capacity plus compliance,” meaning the ability to produce at scale while staying inside the rules, batch after batch.
This is also why the supply side can win even when the developer side gets the headlines.
If more therapies move forward, more clinics open programs, and more prescribers enter the channel. Every one of those programs still needs a consistent, legally manufactured product.
The hallway fills up, and the toll booth collects value from every step forward. That is the logic behind Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) focusing on manufacturing and regulated supply while the rest of the market debates timelines.
The Stock Setup. The Microcap Window Most Investors Miss.
Right now Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) sits in the part of the market where outsized moves can still happen quietly, before the “theme” gets priced in.
The US quote has recently been around $0.23 with a market cap near $22 million, which is why it keeps showing up as a true microcap bargain in a sector that is getting louder by the month.43
The key detail is that this is not a story that needs perfection, it needs survival and execution.
In July 2025, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced a C$3.45 million convertible financing, and the detail that stood out was who wrote the check. The company disclosed that the investors were CEO Dane Stevens and board chair JJ Wilson, meaning it was not a bunch of anonymous investors, it was leadership putting capital on the line while the Australia channel is still early.44
Investors have seen this movie before. MindMed once traded around a quarter in its early days, and the Nasdaq listed shares have traded above $15 in the past year, noting the company completed a 1 for 15 reverse split in 2022.45
That is the bridge into the comps, who scaled, who got the market’s attention, and what early signals showed up first.
The Comps. The Billion Dollar Proof. Then The Public Names Everyone Watches.
The fastest way to understand what this space can become is to look at the last time a regulated plant based category crossed the line into real pharma value.
GW Pharmaceuticals did it.
Jazz Pharmaceuticals completed its acquisition of GW Pharmaceuticals and described the deal value at approximately $7.2 billion.46
That is the kind of endpoint that changes how investors look at “early” categories.
Now the public psychedelic names investors already know, AtaiBeckley, MindMed, COMPASS, Cybin, are largely valued on development pipelines and milestones. Their market caps sit in the hundreds of millions to well over a billion dollars.47,48,49,50,51
And that is where Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) starts to stand out.
It is not being pitched as the next lab breakthrough.
It is being positioned as the legal supplier in the channel, the part of the system clinics and programs actually have to buy from, especially in markets that are already operating under strict rules.
This table frames that difference in one glance.
The punchline is simple.
Most of the big public comps are valued on what they hope to prove.
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is trying to be valued on what clinics must buy, compliant product that can move through regulated channels.
That is also why the gap matters.
If the category keeps expanding, the developer side can win headlines.
The supply side can win repeat orders.
And when a microcap is still sitting around a $22 million valuation while the household ticker comps sit at hundreds of millions and billions, it is the kind of mismatch that does not usually last once the market starts connecting the dots.52
Timeline. What Has Happened. What To Watch Next.
Momentum in this space does not show up all at once.
It stacks.
Paperwork first. Licences next. Product runs next. Then the first shipments that prove the channel is real.
That is the arc Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has been building.
What has already happened
| Date | Milestone |
| June 3, 2024 | Health Canada awarded a Drug Establishment Licence for manufacturing and sale of MDMA and psilocybin capsules.53 |
| June 11, 2024 | Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced its first international shipment of MDMA to Israel, and referenced export authorization progress.54 |
| June 25, 2024 | Health Canada issued export permits tied to supply under Australia’s Authorised Prescriber pathway.55 |
| January 29, 2025 | Optimi reported its largest MDMA capsule batch to date, plus expanded stability data to support shelf life.56 |
| May 5, 2025 | Optimi announced US FDA drug establishment registration, a regulatory step for compliant US supply pathways for registered facilities.57 |
| July 18, 2025 | Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced a C$3.45 million convertible financing and a secured term loan extension, including participation from CEO Dane Stevens and board chair JJ Wilson.58 |
| September 3, 2025 | Optimi announced the commercial launch of natural psilocybin capsules in Australia for treatment resistant depression under the Authorised Prescriber Scheme.59 |
| September 29, 2025 | Optimi announced its largest to date MDMA export to Australia, tied to PTSD therapy supply through authorized networks.60 |
| October 6, 2025 | Optimi announced its psilocybin capsules were selected for a Medibank insurance program expansion in Australia.61 |
Listing and market access items, handled carefully
Optimi’s (CSE:OPTI) (OTCQX:OPTHF) SEC filing states the company has applied to list on the Nasdaq Capital Market, while its shares trade on the CSE, OTCQX, and Frankfurt.62
Market access progress is one of the watch items that can change liquidity quickly, which is why it belongs on the timeline right beside manufacturing and export milestones, not in a separate hype bucket.
The Team With Real Deal Execution Experience And The Open Window
Big healthcare themes attract attention. Turning that attention into durable value usually comes down to people who can operate inside strict rules, keep the lights on, and deliver product the same way every time.
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is built around that kind of operator profile.
Dave StevensCEO and Director, Co founder
Jacob SafarikCFO and Director
Bryan SafarikCOO and Director
JJ WilsonBoard ChairOptimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has disclosed a strategic investment tied to Chip Wilson, the Billionaire Founder of Lululemon.63
This is an exceptional team that investors can trust to get the job done.
The Psychedelic Market Is Entering Its “Proof” Phase And the Window Won’t Stay Open
This category is no longer living only in research papers and fringe conversations.
It is being normalized in public. It is drawing major conferences, serious capital, and steady policy attention.64,65
And the demand backdrop is not small.
Anxiety and depression already represent a gigantic treatment market, Grand View Research estimates about $15.42 billion in 2024, projecting about $19.28 billion by 2030.66
What changes everything is not hype.
It is proof.
Australia already provides a regulated prescription channel, the TGA has stated authorized psychiatrists can prescribe MDMA and psilocybin for specific conditions under strict controls from July 1, 2023.67
In a market like this, the highest leverage layer is often the quiet one.
The supply chain.
Because when programs expand, the same question shows up every time.
Who can legally manufacture. Who can ship. Who can deliver consistent product, batch after batch.
That is exactly the lane Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is trying to own regulated manufacturing and legal supply into clinic channels while the broader category is still being priced like a debate.
Yet the stock still trades like most investors have not connected the dots.
A microcap under a quarter, with a market cap near $22 million, is not where themes usually stay once proof begins stacking.68
The infrastructure is being built. The channel is live. The capital is still moving into the space.
The only question is whether investors recognize the setup before the crowd does.
To stay ahead of the next corporate presentation, press releases, and market access updates for Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF), subscribe now and download the latest investor deck.
